Man Group plc Sells 340,933 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Man Group plc decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 23.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,090,622 shares of the company's stock after selling 340,933 shares during the period. Man Group plc owned 0.50% of Hims & Hers Health worth $26,371,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after buying an additional 40,447 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares in the company, valued at approximately $5,692,221.49. This trade represents a 56.74% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 563,973 shares of company stock valued at $21,951,757. 13.71% of the stock is owned by insiders.

Hims & Hers Health Stock Down 4.2%

Shares of Hims & Hers Health stock opened at $58.54 on Friday. The stock has a market cap of $13.10 billion, a P/E ratio of 133.05 and a beta of 1.84. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The business's 50 day moving average is $34.85 and its 200-day moving average is $33.40.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HIMS shares. Morgan Stanley dropped their target price on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 29th. Piper Sandler reissued a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.